NEUROCRINE BIOSCIENCES INC

NBIX Nasdaq CIK: 0000914475

Company Information

Industry Biological Products, (No Diagnostic Substances)
SIC Code 2836
Entity Type operating
SEC Category Large accelerated filer
State of Incorporation DE
Business Address 6027 EDGEWOOD BEND COURT, SAN DIEGO, CA, 92130
Mailing Address 6027 EDGEWOOD BEND COURT, SAN DIEGO, CA, 92130
Phone (858) 617-7600
Fiscal Year End 1231
EIN 330525145

Financial Overview

FY2025

$3.25B
Stockholders' Equity
$713.00M
Cash & Equivalents
$4.81
EPS

Recent SEC Filings

Form Type Date Filed Document
10-K Annual financial report February 11, 2026 View on SEC
8-K Current report of material events February 11, 2026 View on SEC
4 Insider stock transaction report February 3, 2026 View on SEC
4 Insider stock transaction report February 3, 2026 View on SEC
4 Insider stock transaction report February 3, 2026 View on SEC
4 Insider stock transaction report February 3, 2026 View on SEC
4 Insider stock transaction report February 3, 2026 View on SEC
4 Insider stock transaction report February 3, 2026 View on SEC
4 Insider stock transaction report February 3, 2026 View on SEC
4 Insider stock transaction report February 3, 2026 View on SEC

Annual Reports

10-K February 11, 2026
  • Achieved robust financial year with 18% total revenue growth to $2.15 billion and 25% net income increase to $485 million, driven by INGREZZA and CRENESSITY's successful launch.
  • Maintained a strong financial position with $1.2 billion in cash and equivalents, manageable long-term debt of $300 million, and an excellent current ratio of 3.5x.
View Analysis

Insider Trading

STRONG SELL 6 insiders 8 recent transactions
View Full Insider Trading Profile

Related Companies

Companies in the same industry (SIC: 2836)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.